Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
A randomized, double-blind, placebo controlled, 3-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjogren\'s syndrome (NEPTUNUS-2)
Epistemonikos ID: e35fbfc3ead81fcb569f1122cef904b87f503bd4
First added on: May 13, 2024